Clinical trial · Observational
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study restructured with Central IRB (NCT04996706); accruals reported there.
Summary
Brief summary (as posted)
The goal of this infrastructure grant is to establish and maintain a cohort of over 12,000 non-Hodgkin lymphoma (NHL) patients to support broad and cutting-edge research that identifies clinical (including co-morbid diseases), epidemiologic (including lifestyle and other exposures), host genetic, tumor, and treatment factors, as well as the interaction among these factors, on short and long-term outcomes. These efforts will identify new approaches to improve the survival and well-being of NHL patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival (OS)
- timeFrame
- Short (<5 years), medium (5-10 years), and long-term (>10 years)
- description
- Time from date of diagnosis to date of death
Secondary outcomes (2)
- measure
- Event Free Survival (EFS)
- timeFrame
- Short (<5 years), medium (5-10 years), and long-term (>10 years)
- description
- Time from date of diagnosis to date of first defined event (disease progression, relapse or re-treatment for lymphoma, or death)
- measure
- Lymphoma Specific Survival (LSS)
- timeFrame
- Short (<5 years), medium (5-10 years), and long-term (>10 years)
- description
- Time from date of diagnosis to date of death due to lymphoma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed non-Hodgkin Lymphoma (NHL), within 183 days of enrollment * Patients may have been treated as long as initial NHL diagnosis is within 6 months of enrollment * 18 years of age or older Exclusion Criteria: * Lymphoma diagnosis greater than 184 days from date of consent
References
Publications (1)
- DERIVEDRuan J, Chen Z, Larson MC, Bennani NN, Allen P, Mou E, Wallace D, Mehta-Shah N, Lossos IS, Malpica Castillo LE, Jaye DL, Vega F, Inghirami G, Pongas G, Akkad N, Casulo C, Martin P, Cohen JB, Habermann TM, Maurer MJ, Leonard JP, Friedberg JW, Kahl B, Cerhan JR, Flowers CR, Feldman AL. Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study. Blood Adv. 2026 May 26;10(10):3480-3493. doi: 10.1182/bloodadvances.2025018455. PMID 41707114